Plus   Neg

Cardinal Health Q2 Profit Tops Estimates, Lifts FY Profit View; Stock Up

Cardinal Health (CAH) reported that its net earnings attributable to the company for the second quarter of fiscal 2020 declined to $220 million or $0.75 per share from $280 million or $0.93 per share in the prior year.

In Thursday pre-market trade, CAH is trading at $56.00, up $3.32 or 6.30%.

Non-GAAP earnings per share for the second-quarter were $1.52 compared to $1.29 last year. Analysts polled by Thomson Reuters expected the company to report earnings of $1.22 per share. Analysts' estimates typically exclude special items.

The company raised its fiscal year 2020 non-GAAP earnings per share guidance to a range of $5.20 - $5.40 from the range of $4.85 - $5.10. Analysts expect annual earnings of $5.04 per share.

"With the first half of the year behind us, we are raising our fiscal year 2020 guidance. This increase was driven by improved performance across our Pharmaceutical segment, particularly within our generics program," said Mike Kaufmann, CEO of Cardinal Health.

Second quarter GAAP operating earnings decreased 34% to $334 million, which included a $96 million charge in connection to the recently announced voluntary surgical gown-related recalls. Non-GAAP operating earnings increased 1% to $646 million.

Quarterly revenues was $39.74 billion, an increase of 5% from the prior year. Analysts expected revenues of $39.43 billion for the quarter.

Second quarter revenue for the Pharmaceutical segment increased 6% to $35.7 billion, due to sales growth from Pharmaceutical Distribution and Specialty Solutions customers.

Second quarter revenue for the Medical segment was flat at $4.0 billion. Growth in Cardinal Health at Home was offset by a decline in products and distribution.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT